Complement activation by Proteus mirabilis negatively charged lipopolysaccharides

Abstract

Proteus mirabilis strains are human pathogens responsible for urinary tract infections and bacteremias and may be involved in rheumatoid arthritis. Lipopolysaccharide (LPS, bacterial endotoxin), the major component of the cell wall, is one of the virulence factors of Proteus. In the presented studies, we have investigated complement activation by LPSs isolated from P. mirabilis O10, O23, O30, and O43 strains, which differ in the number of negative COO^— groups on their polysaccharide components. Four P. mirabilis strains studied were sensitive to complement-mediated killing, despite complement binding by their LPSs. The optimal complement binding by LPSs was detected in serum with functional assays for both the classical and alternative pathways.

Complement activation in 80% serum by the smooth, uronic acid, and hexosamine containing P. mirabilis LPSs was not critically determined by the structure of their O-chain polysaccharides. One of four LPSs used as a model, P. mirabilis O10 LPS, fragmented C3 in an LPS dose- and time-dependent manner. It was detected by crossed-immunoelectrophoresis and capture ELISA with anti-C3c antibodies. The lower complement activation by O23 LPS correlates with its reduced C3 fragmentation, compared with three other Proteus LPSs studied. Rabbit anti-O antibodies enhanced the complement binding and factor C3 fragmentation by O10, O23, O30, and O43 P. mirabilis LPSs.

References

Rodman JS Sturvite stones. Nephron 1999; 81 (Suppl. 1): 50—59.

Rozalski A. , Sidorczyk Z. , Kotelko K. Potential virulence factors of Proteus bacilli. Microb Mol Biol Rev 1997; 61: 65—89.

Gikas A. , Samonis G. , Christidou A. , Kofteridis D. , Tselentis Y. , Tsaparas N. Gram-negative bacteremia in non-neutropenic patients: a 3-year review. Infection 1998; 26: 155—159.

Ismail NH , Lieu PK , Lien CT , Ling ML Bacteremia in the elderly. Ann Acad Med Singapore 1997; 26: 593—598.

Maniatis AN , Trougakos IP , Katsanis G. , Palermos J. , Maniatis NA , Legakis NJ Changing patterns of bacterial nosocomial infections: a nine-year study in a general hospital, Chemotherapy 1977; 43: 69—76.

Blankenberg-Spronkels SH , Fielder M. , Feltkamp TE , Tiwana H. , Wilson C. , Ebringen A. Antibodies to Klebsiella pneumoniae in Duch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol 1998, 25: 743—747.

Senior BW , Anderson GA , Morley KD , Kerr MA Evidence that patients with rheumatoid arthritis have asymptomatic `nonsignificant' Proteus mirabilis bacteriuria more frequently than healthy controls. J Infect 1999; 38: 99—106.

Tiwana H. , Wilson C. , Alvarez A. , Abuknesha R. , Bansal S. , Ebringen A. Cross-reactivity between the rheumatoid arthritis-associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun 1999; 67: 2769—2775.

Vukajlovich WS Interaction of LPS with serum complement. In: Ryan JL , Morrison DC. (eds) Bacterial Endotoxic Lipopolysaccharides, Vol II. Baco Raton, FL: CRC Press, 1992; 213—235.

10.

Vukajlovich WS , Hoffman J. , Morrison CD Activation of human serum complement by bacterial lipopolysaccharides: structural requirements for antibody independent activation of classical and alternative pathways. Mol Immunol 1987; 24: 319—331.

11.

Grossman N. , Leive L. Complement activation via the alternative pathway by purified Salmonella lipopolysaccharides is affected by its structure but not its O-antigen's length. J Immunol 1984; 132: 376—381.

12.

Takasaki Ch-JL , Grossman N. , Leive L. Salmonella activated complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen. J Immunol 1983; 130: 1867—1870.

13.

Kaca W. , Swierzko A. , Ziolkowski A. , Amano K-I. , Sanchenkova S. , Knirel YA Serological studies of an acid-labile O-polysaccharide of Proteus vulgaris OX19 lipopolysaccharide using human and rabbit antibodies. Microbiol Immunol 1998; 42: 609—675.

14.

Knirel YuA , Kochetkov NK The structure of lipopolysaccharide of Gram-negative bacteria. III. The structure of O-antigens: a review. Biochemistry (Moscow) 1994; 59: 1325—1386.

15.

Knirel YuA , Kaca W. , Rozalski A. , Sidorczyk Z. Structure of the O-antigenic polysaccharides of Proteus bacteria. Pol J Chem 1999; 73: 895—907.

16.

Radziejewska-Lebrecht J. , Mayer H. The core region of Proteus mirabilis R110/1959 lipopolysaccharide. Eur J Biochem 1989; 183: 573—581.

17.

Sidorczyk Z. , Kaca W. , Brade H. , Rietschel ETh, Sinnwell V, Zähringer U. Isolation and structural characterisation of an 8-O-(4-amino-4-deoxy-β-L-arabinosyl)-3-deoxy-D-manno-octulosonic acid disaccharide in the lipopolysaccharide of a Proteus mirabilis deep rough mutant. Eur J Biochem 1987; 168: 269—273.

18.

Swierzko AS , Cedzynski M. , Knirel YuA et al. Structural and serological studies of the O-antigen of the bacterium Proteus mirabilis OXK (serogroup O3) used in Weil-Felix test. Biochemistry (Moscow) 1997; 62: 28—35.

19.

Vinogradov EV , Thomas-Oates JE , Brade H. , Holst O. Structural investigation of the lipopolysaccharide from Proteus mirabilis R45 (Re-chemotype). J Endotoxin Res 1994; 1: 199—206.

20.

Ziolkowski A. , Shashkov AS , Swierzko ASt et al. Structures of the O-antigen of Proteus bacilli belonging to OX group (serogroup O1-O3) used in Weil-Felix test. FEBS Lett 1997; 411: 221—224.

21.

Klink M. , Brzychcy M. , Ziolkowski A. et al. The comparison of some biological activities of lipopolysaccharides obtained from smooth and rough Proteus mirabilis strains. Acta Microbiol Pol 1998; 47: 141—151.

22.

Ruddy S. Complement. In: Rose NR , de Macario EC , Fahey JL , Fridman H , Penn GM. (eds) Manual of Clinical Laboratory Immunology. 1992 ; 114—123.

23.

Westphal O. , Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further application of the procedure. Methods Carbohydr Chem 1965: 5: 83—89.

24.

Mollnes TE , Garret P. , Bergseth G. Effect of time, temperature and anticoagulants on in vivo complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988 ; 73: 484—488.

25.

Kaca W. , Roth R. Activation of complement by human haemoglobin and by mixture of haemoglobin and bacterial endotoxin. Biochim Biophys Acta 1995; 1245: 49—56.

26.

Holmskov-Nielsen U. , Jensenius JC , Teisner B. , Erb K. Measurements of C3 conversion by ELISA estimation of neo-determinants on the C3d moiety. J Immunol Methods 1986; 94: 1—6.

27.

Garred P. , Mollnes TE , Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988; 27: 329—335.

28.

Sjóholm AG , Selander B. , Östenson S. , Holmstróm E. , Sóderstróm C. Normal human serum of C3q factor D and properdin: its use in studies of complement activation. APMIS 1989; 98: 1120—1128.

29.

Darling A. The Kolomogorov-Smirnov, Cramer-von Mises tests. Math Stat 1957; 28: 823—838.

30.

Snedecor GW , Cochran WG Shortcut and non-parametric methods. In: Statistical Methods . Iowa: Iowa State University Press , 1967; 121—134.

31.

Cedzynski M. , Knirel YA , Rozalski A. , Shashkov S. , Vinogradov V. , Kaca W. The structure and serological specificity of Proteus mirabilis O43 O antigen. Eur J Biochem 1995, 232: 558—562.

32.

Cedzynski M. , Swierzko ASt , Ziolkowski A. et al. Structural and immunochemical studies of two cross-reactive Proteus mirabilis O-antigens, O6 and O23, containing β1-3 linked 2-acetamido-2-deoxy-D-glucopyranose residues. Microbiol Immunol 1988; 42: 7—14.

33.

Shashkov AS , Toukach FV , Ziolkowski A. et al. Structures of the O-specific polysaccharide of the bacterium Proteus mirabilis O30. Biochemistry (Moscow) 1996; 61: 575—579.

34.

Shashkov AS , Senchenkova SN , Toukach FV et al. Structure of the O-specific polysaccharide of the bacterium Proteus mirabilis O10 containing L-altruronic acid, a new component of O-antigens, Biochemistry ( Moscow) 1996; 61: 1100—1105.

35.

Hostetter MK , Gordon DL Biochemistry of C3 and related thiolester proteins in infection and inflammation, Rev Infect Dis 1987; 9: 97—109.

36.

Garred P. , Mollnes TE , Lea T. , Fischer E. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scan J Immunol 1988; 27: 319—327.

37.

McQuillen DP , Gulati S. , Ram S. et al. Complement processing and immunoglobulin binding to Neisseria gonorrheae in vitro simulates in vivo effects. J Infect Dis 1999; 179: 124—135.

38.

Kumar S. , Mathur MD Sensitivity to bactericidal effect of human serum of Proteus strains from clinical specimens. Indian J Pathol Microbiol 1997; 40: 335—338.

39.

Nakagawa K. , Sakiyama H. , Tsuchida T. et al. Complement C1q activation in degeneration articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody. Ann Rheum Dis 1999; 58: 175—181.

40.

Salomaa ER , Viander M. , Saaresranta T. , Terho EO Complement components and their activation products in pleural fluids. Chest 1998; 114: 723—730.

41.

Wilson C. , Senior BW , Tiwana H. , Caparros-Wanderley W. , Ebringer A. , Antibiotic sensitivity and protiocine typing of Proteus mirabilis strains associated with rheumatoid arthritis. Rheumatol Int 1998; 17: 203—205.

42.

Mollnes TE , Redl H. , Hogasåen K. et al. Complement activation in septic baboons by neoepitope-specific assays for C3b/iC3b/C3, C5a and the terminal C4b-9 complement complex (TCC) . Clin Exp Immunol 1993; 91: 295—300.